CereSpir

CereSpir is targeting the emerging field of immuno-neurology via a novel mechanism for the treatment of Parkinson’s disease & other neurodegenerative diseases.

[CereSpir @cerespir]

34% of hospitalized COVID-19 patients showed evidence of CNS involvement according JAMA report.
https://t.co/CAv4l1VOII

#COVID19 #Coronavirus #COVID #SARSCoV2 #nCoV19 #ARDS #BrainInjury #neuroinflammation #Alzheimers #Parkinsons #Biopharma #Biotech #Quarantine

[CereSpir @cerespir]

CereSpir founder and CSO, Dr. Daniel Chain is attending the @adpdnet conference this week in Lisbon. We are looking forward to connecting with leaders in #Alzheimers and #Parkinsons disease research. #ADPD2019

[The Science of Parkinson's @ScienceofPD]

The biotech firm Cerespir @cerespir has announced the formation of an expanded Clinical Advisory Board to support Phase II clinical development of its lead compound Itanapraced in #Parkinsons
https://t.co/s175p2spiL

[CereSpir @cerespir]

We are proud to announce the formation of a world-class Clinical Advisory Board. Chaired by Prof. Robert Hauser, the CAB will support our #Parkinsons disease development program for our compound, itanapraced. Read more: https://t.co/LzdtCUAOZ1 #pharma #biotech #ADPD2019 #PD

[CereSpir @cerespir]

CereSpir founder and CSO, Dr. Daniel Chain is attending the @adpdnet conference this week in Lisbon. We are looking forward to connecting with leaders in #Alzheimers and #Parkinsons disease research. #ADPD2019